Novella Clinical Bolsters Business Development with Three New Hires

, a full service contract research organization (CRO), today announced an expanded business development team with the addition of three Directors of Client Service: Pamela Kennedy, RN; Fabio Mariano and Matthew O’Rourke. 

Kennedy and Mariano, based in the U.S., specialize in , while O’Rourke’s expertise lies with small to mid-size companies in Western Europe. 

Pamela KennedyKennedy joined Novella after leading business development efforts at a global CRO in the medical device and diagnostic space. With more than 30 years of experience in the medical device and pharmaceutical industries, she has held positions as an oncology nurse, clinical research associate, project manager, and clinical specialist with a medical device organization. Kennedy also previously led a team of clinical specialists at Cyberonics, the maker of a Class III implantable neuromodulation device, where she co-authored a successful regulatory submission for premarket approval.

Fabio MarianoMariano most recently served as an associate director of business development for an academic research organization where he specialized in developing collaborations with manufacturers of high-risk, minimally invasive medical devices. He began his career in a management consulting firm, advising senior management of life sciences organizations on growth strategy. Mariano has earned certifications from the Regulatory Affairs Professional Society after passing both the U.S. and European Union Regulatory Affairs Certification (RAC) exams, and holds an A.B. in Biochemical Sciences from Harvard University.

Matthew O’RourkeO’Rourke, headquartered in Stevenage, England, is a seasoned business development professional with a career spanning nearly 10 years in a variety of biopharmaceutical services sales roles. Experienced in selling full service CRO capabilities, he also has expertise in clinical trial software. O’Rourke serves biotechnology and medical device clients in Western Europe.

“Novella’s continued growth dictated the need for additional, highly qualified client service directors,” said , executive vice president, Novella Clinical. “Our new additions add value to sponsors from day one, understanding both the clinical and regulatory challenges facing industry today.”

Novella’s more than 800 global professionals provide a full range of clinical research outsourcing solutions as well as flexible resourcing models for oncology, medical device and biopharma companies. Currently supporting clients in 19 European countries, Novella continues to expand throughout the EU.  

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.